Indicatie
FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated: - for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
In andere landen
Dezelfde werkzame stoffen in andere registers, met hetzelfde merk eerst.
Nationale vermeldingen
De nationale registers waarin dit EU-geneesmiddel staat.